CF
ADVM

Corebridge Financial’s Adverum Biotechnologies ADVM Stock Holding History

Corebridge Financial’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,192
Closed -$44.5K – 60
2025
Q1 		$44.5K Sell
10,192
-151
-1% -$681 ﹤0.01% 2759
2024
Q4 		$48.3K Sell
10,343
-780
-7% -$5.25K ﹤0.01% 2838
2024
Q3 		$78.1K Sell
11,123
-69
-0.6% -$501 ﹤0.01% 2724
2024
Q2 		$76.9K Buy
+11,192
New +$104K ﹤0.01% 2741

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Corebridge Financial's ADVM Position: Q2 2025 in Review

Corebridge Financial sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 10,192 shares — an estimated $44.5K sold.

Corebridge Financial first reported a position in ADVM in Q2 2024 and held it in 4 quarters. The position peaked at $78.1K in Q3 2024. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • Corebridge Financial reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 10,192 Adverum Biotechnologies shares in Q2 2025, an estimated $44.5K.
  • Corebridge Financial first reported a position in Adverum Biotechnologies in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Adverum Biotechnologies position peaked at $78.1K in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.